All In Biotech

BLA 761083 · Genentech INC

Hemlibra

Emicizumab · Injection

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 8, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Nov 16, 2017

Approved uses

3

Original approval plus efficacy supplements

Registered trials

36

19 Phase 3, 10 recruiting

FAERS reports

12,873

4,932 serious, 416 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: THROMBOTIC MICROANGIOPATHY AND THROMBOEMBOLISM Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur. WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM See full prescribing information for complete boxed warning. Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of...

What it is approved for

From the label in effect Jul 11, 2025.

HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. HEMLIBRA is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. ( 1 )

Mechanism: HEMLIBRA bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 4, 2018 Supplement 4 · Efficacy · priority review OrphanLabelLetter
  • Oct 4, 2018 Supplement 2 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Nov 16, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
4 products under this application
  • HEMLIBRA · EMICIZUMAB 60MG/0.4ML · INJECTABLE, INJECTION · Prescription
  • HEMLIBRA · EMICIZUMAB 105MG/0.7ML · INJECTABLE, INJECTION · Prescription
  • HEMLIBRA · EMICIZUMAB 30MG/ML · INJECTABLE, INJECTION · Prescription
  • HEMLIBRA · EMICIZUMAB 150MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Emicizumab" as an intervention, any sponsor and status, largest first.

All 36 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • haemorrhage4,767
  • haemarthrosis890
  • off label use826
  • no adverse event812
  • fall705
  • arthralgia539
  • epistaxis437
  • contusion427
  • head injury382
  • pain352
  • muscle haemorrhage332
  • limb injury257

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20175
2018159
2019318
2020527
2021594
2022973
20232,901
20243,633
20252,066
20261,696

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Hemlibra (Emicizumab-Kxwh) · HCPCS J7170

2024 spending

$230M

Beneficiaries

438

5,480 claims

Per beneficiary

$525,221

2024 ASP limit $51.67 per unit

View as table
YearSpending
2020$147,878,934
2021$178,638,413
2022$203,557,787
2023$233,254,207
2024$230,046,953

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 54 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.